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Abstract
Research points to postprandial glucose and TAG measures as preferable assessments of cardiovascular risk as compared with fasting values.
Although elevated postprandial glycaemic and lipaemic responses are thought to substantially increase chronic disease risk, postprandial
glycaemia and lipaemia have historically only been considered separately. However, carbohydrates and fats can generally ‘compete’ for
clearance from the stomach, small intestine, bloodstream and within the peripheral cell. Further, there are previous data demonstrating that the
addition of carbohydrate to a high-fat meal blunts the postprandial lipaemic response, and the addition of fat to a high-carbohydrate meal
blunts the postprandial glycaemic response. Thus, postprandial glycaemia and lipaemia are interrelated. The purpose of this brief review is
2-fold: ﬁrst, to review the current evidence implicating postprandial glycaemia and lipaemia in chronic disease risk, and, second, to examine
the possible utility of a single postprandial glycaemic and lipaemic summative value, which will be referred to as the metabolic load index.
The potential beneﬁts of the metabolic load index extend to the clinician, patient and researcher.
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Meal consumption, particularly meals that are high in fat,
processed sugars and total energy content, results in transient
elevations in blood glucose and lipids. These elevations, termed
postprandial glycaemia and lipaemia, respectively, have both
been linked to the progression of CVD, primarily through a
resultant rise in oxidative stress, inﬂammation and endothelial
dysfunction(1,2). Thus, exaggerated postprandial glycaemia and
lipaemia, if experienced several times per day, represent a clear
metabolic challenge to homoeostasis. Individuals in Western
society are thought to spend most of their waking hours in the
postprandial state(3), and thus in a near-constant state of post-
prandial challenge, which could be ampliﬁed to prolonged
dysmetabolism in the case of individuals at risk for metabolic
disease. Hence, recent research has been devoted to better
understand how the body, in health and disease, handles these
metabolic excursions. Typically, postprandial glycaemic and
lipaemic responses are characterised by measuring blood
glucose and TAG serially for a given amount of time after a meal
and, from these data, calculating AUC. Although these methods
are effective in characterising the glycaemic and lipaemic
responses independently, previous efforts have not considered
them simultaneously. However, meals typically contain both
carbohydrate and fat, as well as some protein; thus, it may be
worthwhile to consider the summative metabolic response of
both carbohydrate and lipids, as opposed to simply focusing on
just one or the other. This brief review will ﬁrst consider post-
prandial glycaemia and lipaemia independently in relation to
metabolic status and CVD risk, followed by a discussion of the
potential utility of a postprandial metabolic load index (MLI)
that combines glycaemia and lipaemia together, indicating total
circulating energy availability.
Blood glucose and metabolic status/risk
Fasting blood glucose, glycated Hb and cardiovascular risk
Assessment of long-term glucose control via glycated Hb
(HbA1c) or fasting glucose levels is commonly used as a
valuation of cardiovascular and diabetic risk(4). This practice is
based on several epidemiological studies linking HbA1c levels
or impaired fasting glucose to heart or vascular disease(5,6). For
example, the United Kingdom Prospective Diabetes Study
found that mean HbA1c over time in the cohort was a valuable
predictor of ischaemic heart disease(5). Speciﬁcally, the data
showed that for every 1% increase in HbA1c there was an
approximately 10% increase in heart disease risk(5). With regard
to fasting glucose levels, a meta-analysis of nearly 700 000
people found that fasting blood glucose was modestly and
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non-linearly associated with vascular disease in diabetic indi-
viduals(6). Finally, an epidemiological study in US adolescents
also found a link between impaired fasting glucose and
CVD risk factors, including high fasting insulin, total and
LDL-cholesterol, TAG, systolic blood pressure and low
HDL-cholesterol(7). Thus, fasting glucose and HbA1c measures
are considered by some to be valuable screening tools for
type 2 diabetes and indeed are commonly used in clinical
environments. However, it is interesting to note that early in the
development of type 2 diabetes postprandial glucose tolerance
plays a large role, whereas fasting glucose plays a more
substantial role later in the disease process(8). In other words,
derangements in fasting blood glucose take longer to develop,
whereas impairments in post-challenge glucose tolerance
could be observed earlier.
Post-challenge/postprandial blood glucose and
cardiovascular risk: epidemiological studies
In contrast to impaired fasting glucose, there are substantial data
suggesting that impaired glucose tolerance should be pre-
ferentially considered when assessing chronic disease risk(9,10).
To support this, Tominaga et al.(9) found that survival rates
in frank diabetes and impaired glucose tolerance were sig-
niﬁcantly lower than individuals with impaired fasting glucose,
and further concluded that impaired glucose tolerance was a
risk factor for CVD, but impaired fasting glucose was not. This
ﬁnding was also supported by Blake et al.(10) who followed 937
non-diabetic individuals for nearly 10 years and found that
impaired glucose tolerance was phenotypically different from
impaired fasting glucose, and is associated with increased
presence of CVD risk factors. Further, the authors reported that
individuals with impaired fasting glucose had CVD risk factors
that were similar to individuals with normal glucose tolerance,
further weakening the apparent utility of fasting glucose as
a measure of CVD risk(10).
A common way to assess glucose tolerance is the oral glucose
tolerance test (OGTT), in which a plasma glucose measurement
is made 2 h after the ingestion of a standard glucose load,
typically 75 or 100 g(11). There are numerous studies linking 2-h
glucose levels following an OGTT with CVD risk(12–14). The
Chicago Heart Study found that 2-h post-challenge glucose
predicted all-cause mortality in a cohort of 11 554 white men
and 666 black men(13). Similarly, results from the DECODE
(Diabetes Epidemiology: Collaborative analysis of Diagnostic
criteria in Europe) study indicated that high blood glucose
following an OGTT was associated with an increased risk of
death, independent of fasting glucose(14). Finally, the Helsinki
Policeman Study, Paris Prospective Study and the Whitehall
Study all found that all-cause and CHD mortality was predicted
by 2-h post-challenge glucose following an OGTT(15–18).
There are certainly drawbacks to the use of the OGTT to
assess glucose tolerance and subsequent CVD risk. Consump-
tion of 75–100 g of pure glucose rarely happens in daily life,
and thus it does not perfectly simulate the real-life glucose
challenges faced daily by many people. Further, the extent of
glycaemia experienced following a meal is dependent on the
entire contents of the test meal challenge. Hence, to better
understand how the body tolerates glucose, it is important
to challenge the metabolic system with a test meal that is
representative of that experienced during daily living, such
as a mixed meal. For this reason, some studies have utilised test
meals that include fat and protein when assessing the glycaemic
response and subsequent CVD risk(19,20). Similar to studies
using OGTT, the Diabetes Intervention Study found that
the postprandial glycaemic response to a mixed meal was a
signiﬁcant predictor of CHD(19). There is evidence that the
glucose response seen following an OGTT is very similar to a
mixed meal (in this case, consisting of wafers, rapeseed oil and
honey), which suggests that the OGTT may have utility in
assessing glucose tolerance, despite its apparent drawbacks(20).
Thus, the glucose response to an OGTT may potentially be
used as a proxy for, but is not identical to, true-to-life post-
prandial glycaemia(2).
Post-challenge/postprandial blood glucose and
cardiovascular risk: intervention studies
An important intervention study connecting postprandial/post-
challenge hyperglycaemia to CVD risk is the STOP-NIDDM
(Study to Prevent Non-Insulin Dependent Diabetes Mellitus)
trial(21). Results from the STOP-NIDDM trial show that treatment of
individuals with impaired glucose tolerance with acarbose, an
α-glucosidase inhibitor that speciﬁcally reduces post-challenge
glycaemia, is associated with a substantial (36%) reduction in
the likelihood of progressing to overt diabetes(21). In addition,
acarbose treatment was associated with a 34% risk reduction
of developing hypertension and a 49% risk reduction for
developing cardiovascular events(21). Finally, in a subgroup of
participants in which carotid intima media thickness was
measured, treatment with acarbose was associated with a
signiﬁcantly attenuated progression of intima media thickness
compared with the control group(22). This work was subsequently
supported by a meta-analysis that indicated a signiﬁcant reduction
in cardiovascular events following acarbose treatment in diabetic
individuals, even after consideration of other risk factors(23).
Another important intervention study by Esposito et al.(24)
investigated the effects of two insulin secretagogues (compounds
that promote insulin secretion) repaglinide and glyburide, which
have differing effectiveness on hyperglycaemia (with repaglinide
being more effective), on surrogate measures of atherosclerosis.
After 1 year, 52% of diabetic patients receiving repaglinide and
18% of participants receiving glyburide displayed carotid intima
media thickness regression(24). Further, C-reactive protein and IL-6,
both markers of systemic inﬂammation, decreased more in the
repaglinide group than in the glyburide group(24). These ﬁndings
suggest a direct link between postprandial/post-challenge glucose
intolerance and CVD.
Mechanisms behind blood glucose and cardiovascular risk
How may post-challenge hyperglycaemia and CVD be
mechanistically linked? First and foremost, glucose intolerance
is typically a feature of insulin resistance(25). Insulin resistance
may result in deterioration of metabolic homoeostasis in terms
of both glucose and circulating NEFA(25). Not only do type 2
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diabetes patients experience impaired clearance of glucose by
insulin they are also resistant to insulin-induced suppression
of NEFA release(26). If not controlled, the elevated NEFA levels will
precipitate elevated hepatic glucose production(27). The increased
hepatic glucose production in combination with reduced insulin-
stimulated glucose uptake produces a spike in blood glucose
levels(25). The elevation of both fasting and postprandial glycaemia
results in numerous adverse outcomes (Fig. 1).
To start, diabetic individuals typically experience endothelial
dysfunction early in the disease process(28). Speciﬁcally, the
vasodilatory response is not only diminished in diabetics but is
also related to glycaemic control(28), which is supported by
ﬁndings from in vivo studies demonstrating that hypergly-
caemic spikes induce endothelial dysfunction in both normal
and diabetic subjects(29,30). Similarly, there are data showing
that during the postprandial period in diabetic participants
decreased ﬂow-mediated dilation is negatively associated with
the extent of postprandial glycaemia(31). In addition, rapid
upsurges of glucose result in non-reversible glycosylation of
proteins(32). These advanced glycosylated end products bind to
endothelial smooth muscle receptors, precipitating increased
endothelial permeability and vascular smooth muscle cell
proliferation(2,32).
Additional avenues by which postprandial hyperglycaemia
may be mechanistically linked to CVD are increased blood
coagulation and/or thrombosis. When hyperglycaemia is induced
experimentally, there is an increase in platelet aggregation(33),
fragments of prothrombin(34) and a shortening of the half-life of
ﬁbrinogen(35). There also may be an immune and inﬂammatory
component to postprandial hyperglycaemia. Increases in TNF-α
and IL-6 have been shown to occur both in the context of post-
prandial hyperglycaemia(36) and with a hyperglycaemic clamp(37).
In addition, circulating levels of intracellular adhesion molecule-1
(ICAM-1) have been demonstrated to increase substantially
following post-challenge glycaemia, suggesting activation of one
of the most proximal steps of the atheromatous lesion process(38).
Finally, LDL oxidation is known to increase in type 2 diabetic
patients after meal consumption and is inversely proportional to
the degree of metabolic control(39,40). Collectively, these ﬁndings
provide support for the notion of direct metabolic and physiologic
links between postprandial/post-challenge hyperglycaemia
and CVD risk.
TAG and metabolic status/risk
Fasting TAG and CVD risk
Similar to fasting blood glucose, elevated fasting TAG levels are
typically thought to be a risk factor for CVD. However, the data
supporting this relationship are somewhat equivocal. It appears
that, unlike HDL-cholesterol and LDL-cholesterol for which
there are strong, consistent relationships with cardiovascular
risk(41), the data do not clearly reveal fasting TAG to be an
independent risk factor for CVD. For example, the relationship
Postprandial
lipaemia
Postprandial
hyperglycaemia
↑ VLDL secretion/
hypertriacylglycerolaemia
Elevated NEFA and
glucose
over time...
Impaired insulin-
induced glucose
uptake
↑ Carotid intima-
media thickness
Endothelial lesion
development
Impaired endothelial
function
↑ Low-grade
endotoxaemia
↑ Makers of
inflammation
TNF- IL-6, IL-8,
neutrophils
↑ Subendothelial
retention of lipoproteins/
LDL oxidation via ROS ↑ Intracellular
adhesion molecules
if not maintained...
Hyperinsulinaemia
Hypertension
↑ Blood coagulation/
thrombosis
CVD risk
Atherosclerosis, myocardial infarction
coronary artery disease, etc.
Fig. 1. Postprandial lipaemia, postprandial hyperglycaemia and CVD risk. Multiple potential mechanisms exist to explain the connection between postprandial
dysmetabolism (glycaemia and lipaemia) and CVD risk. Similar primary facets involved in both postprandial glycaemia and lipaemia are elevated markers of systemic
inflammation, increased subendothelial retention of lipoproteins and increased intracellular adhesion molecules. See the ‘Mechanisms behind blood glucose and
cardiovascular risk’ and ‘Mechanisms behind TAG and cardiovascular risk’ sections for more details. ROS, reactive oxygen species.
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between TAG levels and cardiovascular risk, although
signiﬁcant in univariate analyses, sometimes disappears or
weakens in multivariate analyses that control for HDL-
cholesterol(42). In addition, measurement of TAG, clinically or
experimentally, can ﬂuctuate greatly based on recent dietary
composition, physical activity or weight status(42,43). However,
some evidence does point to the utility of measuring fasting
TAG in order to assess cardiovascular risk(44,45). First, the
Copenhagen Male Study, which featured an 8-year follow-up of
nearly 3000 middle- to older-aged men, found that men in the
middle and highest tertile groups of fasting TAG levels had an
increased risk for ischaemic heart disease, as well as a risk gra-
dient based on TAG levels, even after being stratiﬁed for HDL-
cholesterol(44). Intriguingly, the middle and highest tertiles of
TAG levels displayed relative risks for ischaemic heart disease of
1·5 and 2·2, respectively, compared with the lowest tertile, even
after consideration of LDL-cholesterol, HDL-cholesterol, physical
activity, hypertension, type 2 diabetes, smoking, BMI and age(44).
Further, a meta-analysis that included 46 413 men and 10864
women across seventeen population-based, prospective studies
found that elevated TAG levels were associated with an
approximately 30% increase in CVD risk in men and an
approximately 75% increase in women(45). Although controlling
for HDL-cholesterol and LDL-cholesterol indicated a lowered
associated risk between TAG and CVD, having elevated TAG
levels was still a statistically signiﬁcant risk factor.
Postprandial TAG and CVD risk
Although the clinical and experimental utility of measuring
fasting TAG remains equivocal, there is substantial evidence
suggesting that the transient, extensive rise in blood lipids
(namely, TAG) following a meal can have direct atherosclerotic
effects(46). Thus, postprandial lipaemia is considered by many
to be an independent CVD risk factor(2,47). First, whereas the
relationship between fasting TAG levels and cardiovascular risk
can be confounded by HDL-cholesterol levels(42), there are data
demonstrating that as TAG increase in the postprandial period
there is a related decrease in certain HDL-cholesterol subfrac-
tions(48). Furthermore, postprandial levels of certain TAG-rich
lipoprotein subfractions (particularly, small chylomicron
remnants) were found to be correlated with coronary lesion
progression in thirty-two post-infarction men, even after
controlling for HDL-cholesterol and dense LDL apo B(49). In a
landmark study by Patsch et al.(46), forty control subjects and
sixty-one subjects with severe coronary artery disease (CAD)
completed meal tolerance tests in order to assess postprandial
lipaemia and CAD risk. Measures of postprandial lipaemia
(peak and AUC values) were signiﬁcantly greater in the CAD
patients than in the controls(46). Furthermore, postprandial
lipaemic values predicted the presence or absence of CAD with
68% accuracy by logistic regression analysis(46). Although not
synonymous with postprandial TAG, non-fasting TAG still
provide a way to examine the blood lipid levels that a person
may experience in daily life, and are more practical for
large-scale studies. In a prospective study of 26 509 initially
healthy women, fasting and non-fasting TAG were assessed
over approximately 11 years of follow-up, and hazard ratios for
incident cardiovascular events were determined(50). Although
both baseline fasting and non-fasting TAG levels correlated
with cardiac risk factors and markers of insulin resistance, the
relationship disappeared with regard to fasting TAG values
after covarying total cholesterol, HDL-cholesterol and measures
of insulin resistance(50). On the other hand, the relationship
between non-fasting TAG and cardiac events remained
robust even in the fully adjusted model (increasing tertiles of
non-fasting TAG levels: 1 (reference tertile), 1·44 and 1·98),
thus supporting the use of non-fasting (or postprandial)
TAG measures over fasting TAG measures when predicting
cardiovascular risk(50).
Mechanisms behind TAG and cardiovascular risk
The primary mechanism explaining how elevated TAG levels,
be it fasting, non-fasting or postprandial, induce CVD is
the subendothelial retention of lipoproteins, which initiates
atherogenesis(51). Circulating chylomicrons and large VLDL
molecules, which are rich in TAG, are too big to penetrate the
arterial wall, but smaller dense VLDL and other remnant
molecules can enter the arterial wall and bind to proteogly-
cans(52). The presence of these lipoprotein and remnant mole-
cules, which can be elevated during acute postprandial
lipaemia, initiates a local inﬂammatory response that includes
macrophages and T cells that promote subsequent lesion
development(51). This hypothesis is in line with studies
demonstrating that the extent of coronary blockage and sub-
sequent CVD risk is associated with the degree of postprandial
lipaemia following a high-fat meal(46,49). In addition, there are
also data suggesting that carotid intima media thickness is
signiﬁcantly positively associated with the postprandial lipaemic
response in both healthy and diabetic individuals(53,54). Further,
many studies have provided evidence suggesting that markers
of inﬂammation signiﬁcantly increase in the presence of
postprandial lipaemia, including plasma IL-8, neutrophil counts,
ICAM-1 and TNF-α(36,55,56).
Another avenue by which lipaemia may increase cardiovas-
cular risk is impaired endothelial function. It has been shown
that endothelial function, measured as brachial artery blood
ﬂow, can be impaired in response to a high-fat meal, providing
a potential mechanistic link between postprandial lipaemia
and heart disease, independent of cholesterol(57). Interestingly,
a study by Erridge et al.(58) found a signiﬁcant increase in
circulating bacterial endotoxin following a high-fat meal,
suggesting that low-grade endotoxaemia may contribute to the
inﬂammatory state that occurs after a high-fat meal, and
may explain the endothelial dysfunction that occurs during
postprandial lipaemia. As a whole, evidence suggests several
overlapping mechanisms by which elevated TAG levels, fasting
or postprandial, may lead to increased CVD risk (Fig. 1).
Similarities between glycaemia and lipaemia
As postprandial glucose and lipids both appear to ﬂuctuate from
homeostasis on a daily basis in normal living, and more
importantly these aberrant responses appear to be strongly
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linked to cardiovascular risk, it may be worth considering them
in unison, compared with independently as is currently com-
mon practice. However, in order to understand the ways in
which glycaemia and lipaemia are linked, it is vital to discuss
and recognise the overlapping metabolic pathways shared
between dietary carbohydrate and lipids.
Uptake into peripheral cells
Circulating blood glucose is taken up by human cells via
facilitated diffusion across the plasma membrane. There are at
least six known GLUT that perform this task(59). GLUT4 is the
most widely acknowledged, as it is expressed on adipose cells,
skeletal muscle cells, cardiac muscle cells and other insulin-
sensitive cells(60). As insulin binds to its receptor, GLUT4 is
translocated to the plasma membrane and glucose enters
the cell(60).
There are two primary ways in which lipid (speciﬁcally, fatty
acids) can become available for energy use in the cytosol of a
given cell. One option is for fatty acids to diffuse across the
plasma membrane of the cell, similar to carbohydrate. These
incoming fatty acids are either: (1) freed from TAG in lipopro-
teins by the action of lipoprotein lipase (LPL); (2) circulating
bound to albumin; or (3) circulating as NEFA. The other option
for fatty acids to become available in the cytosol is liberation
from intracellular lipid pools. Regardless of how they arrive in
the cytosol, fatty acids are typically found linked to fatty acid
binding protein(61).
In discussing the uptake of fat and carbohydrate into
peripheral cells, it is worth considering the shared relationship
of both glucose and fatty acids with the hormone insulin. As
discussed previously (see the ‘Mechanisms behind blood
glucose and cardiovascular risk’ section), insulin works to both
allow entrance of glucose into peripheral cells and suppress the
release of NEFA into circulation. Thus, insulin clearly plays a
major role in the regulation of circulating glucose and fatty
acids. Further, as elevations in circulating NEFA can precipitate
augmented hepatic glucose production(27), perturbations in the
level of one substrate can affect the other. Therefore, based
on the data there is a relationship between an individual’s
circulating levels of insulin, glucose and fatty acids, and
consequently derangement of one substrate or mechanism (e.g.
insulin sensitivity) can produce a downward metabolic
spiral(25).
Another relevant consideration when discussing uptake of
carbohydrate and lipid is the effect of dietary fats on insulin
resistance. Evidence suggests that increased levels of fatty acids,
both in the diet and in circulation, can play a role in the
development of insulin resistance(62). The level of fatty acids in
the diet and circulation, as well as a the type, that is the
proportion of SFA relative to unsaturated fatty acids, will be
reﬂected in the fatty acid composition of peripheral cell mem-
branes(63). Higher levels of SFA in cell membranes appear to
substantially hinder insulin action(62). In addition, as Randle
et al.(64) ﬁrst suggested in 1963, elevated fatty acids are likely to
compete with glucose for clearance via oxidation, resulting in
elevated blood glucose, and thus high fatty acid intake can be
directly responsible for the body’s inability to clear glucose.
Over time this could lead to severely impaired glucose disposal
and overt diabetes. It also appears that high levels of myocel-
lular lipid can impair insulin sensitivity(65,66). As the traditional
Western diet is typically high in fat, especially SFA, these
ﬁndings represent additional ways in which dietary lipid and
carbohydrate intake are interconnected in the determination
of chronic disease risk.
Major metabolic pathways
The initial step towards obtaining energy from glucose present
in the cytosol is glycolysis, followed by the Kreb’s cycle and the
electron transport chain(67,68). Glycolysis is a set of ten reactions
by which glucose is converted to two molecules of a pyruvate,
with two ATP molecules and one hydrogenated NADH mole-
cule produced in the process. The newly generated pyruvate
can have one of several different destinations, including
entering the mitochondria and being converted into acetyl CoA
via pyruvate dehydrogenase, or being converted to alanine or
other amino acids, lactic acid, oxaloacetate or back to glucose.
In order to obtain energy from the fatty acids located in the
cytosol, the ﬁnal destination is the Kreb’s cycle as well, although
there is a longer and more complex path. The process of fatty
acid oxidation, known as β-oxidation, is a four-step process that
results in the products FADH2, NADH+H+ and acetyl CoA
being produced. The acetyl CoA produced via β-oxidation can
either travel to the liver to form ketone bodies or condense with
oxaloacetate to form citrate and enter the citric acid cycle.
(It should be noted that odd-chain fatty acids and unsaturated
fatty acids require additional steps and/or enzymes compared
with even-chain SFA, which were discussed here for simplicity.)
Acetyl CoA, whether its original source was lipid, carbohy-
drate or otherwise, enters the citric acid cycle, also known as
the Kreb’s cycle, where it condenses with oxaloacetate to form
citrate. Eight subsequent reactions occur, after which oxaloa-
cetate is again present, thus making the process cyclic. During
one round of the citric acid cycle, two carbon dioxide mole-
cules, three NADH+ molecules, one FADH2 molecule and one
ATP molecule are generated. NADH+ and FADH2 can then
transfer their electrons to the electron transport chain, through
which oxidative phosphorylation produces more ATP.
An overwhelmed pathway
It is important to consider the postprandial glycaemic and
lipaemic responses together because they ultimately share
similar destinations or outlets. Although details vary depending
on the physiological site, carbohydrates and fats can generally
‘compete’ for clearance from the stomach, small intestine,
bloodstream and within the peripheral cell. Speciﬁcally with
regard to the latter, both carbohydrates and lipids are largely
converted to acetyl CoA and enter the citric acid cycle and the
electron transport chain, as previously discussed. Consumption
of large-volume, energy-dense and easily digestible food
precipitates substantial spikes in NEFA, TAG and blood
glucose. As the fat and carbohydrate compete for clearance,
the excessive upsurge of metabolic energy overwhelms the
metabolic capacity of the mitochondria within adipose and
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skeletal muscle cells, as well as all other metabolically active
cells(69). Fatty acids and glucose swamp the citric acid cycle,
which promotes the excess production of NADH+ that outper-
forms the electron transport chain(2). The buildup of NADH+
raises the proton gradient within the mitochondria, promoting
the transfer of single electrons to O2, generating free radicals
that include the superoxide anion(2,70,71). The elevated pro-
duction of reactive oxygen species will subsequently oxidise
LDL particles that have penetrated the endothelium and entered
the subendothelial space(72,73). Oxidised LDL particles lead to
an inﬂammatory cascade in the following ways: (1) increased
expression of cellular adhesion molecules, which promote
attachment and penetration of immune cells to the
endothelium(74); (2) elevated release of pro-inﬂammatory
cytokines(75); (3) activation of endothelial and smooth muscle
cells(76); and (4) increased uptake of the oxidised LDL
particles by M2 macophages, triggering additional release of
pro-inﬂammatory cytokines(73). Thus, the subendothelial
penetration of lipoproteins and their subsequent oxidation
by reactive oxygen species – both downstream results of the
energy excess in circulation – can precipitate increased inﬂam-
mation, sympathetic tone and vasoconstriction, as well as throm-
bogenicity and advanced glycation end products – all of which
can increase an individual’s CVD risk(2,69,77,78). Therefore, as both
glucose and fatty acids can ‘team up’ to overwhelm the metabolic
machinery of the body and produce the above response, it does
not seem unreasonable to consider the glycaemic and lipaemic
responses in the postprandial period together.
Summing glucose and TAG to characterise ‘metabolic
load index’
Given the potential utility and value in assessing postprandial
glycaemia and lipaemia in unison, we suggest a summative
index that we have termed ‘metabolic load index’. To create an
MLI score, the clinician or scientist could simply combine the
values of circulating blood glucose and TAG:
MLI
mg
dl
 
=TAG
mg
dl
 
+Glu
mg
dl
 
:
For instance, if considering a single time point, glucose and
TAG could be summed to determine the MLI in mg/dl for that
point in time. The principle would remain the same if AUC was
being considered: simply sum the TAG and glucose AUC
values. In this way, the researcher and clinician could get an
idea of the overall metabolic load, or challenge, that the patient
or participant is experiencing, as well as the volume of circu-
lating available energy, either at that speciﬁc time point or over
time (such as following a meal).
Fig. 2 demonstrates MLI utilising published data from our
laboratory, which displays hourly changes in glucose, TAG and
MLI following a high-fat meal(79). The test meal consisted of ice
cream and whipping cream (1 g/kg body weight carbohydrate
and 1 g/kg body weight fat, approximately 60% fat, 20%
carbohydrate). MLI is the sum of TAG and glucose at each time
point. It is interesting to note that, as the meal contained
approximately 60% fat, the MLI closely follows the change in
TAG over time, most likely because of the large contribution of
fat to the total energy content of the meal. Similarly, as the
carbohydrate load in the meal was relatively low, the blood
glucose response was marginal and negligibly affected the MLI
during the postprandial period. This test meal was high in fat,
and few people would likely deem the meal ‘healthy’. How-
ever, if blood glucose response was the main/only outcome of
interest, the conclusion after consumption of such a meal could
be that metabolic disturbance was minimal, although this is
clearly not the case when the TAG and MLI responses are
considered together. Thus, clinically, assessment of MLI could
provide a measurement of metabolic challenge or disturbance
without biasing towards glucose or TAG alone. Further, con-
sideration of MLI may be more relevant when determining
metabolic responses to mixed meals that are more typically
consumed in daily living, as compared with an all-lipid or
all-carbohydrate meal, as is used in an OGTT.
To support this notion, there is evidence indicating that
postprandial fat and carbohydrate metabolism are not inde-
pendent processes, and alterations in one can affect the other.
An early study elucidating this relationship was conducted by
Albrink et al.(80) in 1958 in which a 60-g fat meal was consumed
with and without 100–250 g of added glucose. The authors
found that the addition of glucose either diminished or com-
pletely abolished the postprandial rise in TAG, depending on
the amount of added glucose(80). In a related study several years
later, Mann et al.(81) found that postprandial lipaemia was
cleared more slowly following a meal that contained a glucose
load compared with a meal that contained sucrose. These early
ﬁndings have been supported by several more recent studies
demonstrating similar results(82–84). In a randomised cross-over
study, Westphal et al.(84) investigated the effect of adding 75 g
of glucose to a high-fat meal compared with a high-fat meal
without the added glucose on TAG, VLDL and chylomicrons
(Fig. 3). The addition of glucose to the meal resulted in a delay
in the TAG response, as well as a lower peak(84). There was also
a 42% reduction in incremental AUC for the meal with glucose
0 1 2 3 4 5 6 7 8
0
100
200
300
400
500
Time (h)
m
g/
dl
Fig. 2. Hourly changes in glucose, TAG and metabolic load index following a
high-fat meal. These data were taken from a previously published study in our
laboratory(79). This figure displays glucose (●),TAG (■) and metabolic load
index (Δ) at baseline (time 0) and for 8 h during the postprandial period
following consumption of a high-fat meal. With these data, fasting and
postprandial metabolic load index can be determined by adding the TAG and
glucose value at each time point. See the ‘Summing glucose and TAG to
characterise “metabolic load index”’ section for more details. Values are
means, with their standard errors.
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compared with the fatty meal alone. Finally, there was a
delayed chylomicron response and a blunted VLDL response.
A similar investigation by Knuth et al.(83) demonstrated a
reduction in postprandial plasma TAG in women following a fat
meal containing additional carbohydrate compared with a fat
meal alone. Collectively, these studies suggest that the addition
of carbohydrate to a meal and the resultant glycaemic response
alters the postprandial rise in TAG. The interrelationship
between postprandial glycaemia and lipaemia also holds when
adding fat to a high-carbohydrate meal(85,86). In an investigation
by Collier & O’Dea(85), when 50 g of fat (as butter) was added to
50 g of carbohydrate (as potato), the postprandial glucose
response was signiﬁcantly blunted compared with ingestion of
potato alone. This mitigation was likely a result of delayed
glucose absorption in the small intestine, consequent to a
fat-induced repression of gastric emptying. Together, these
ﬁndings suggest that postprandial glucose and lipid metabolism
are not independent processes – rather they are interrelated,
and consequently it would be valuable to consider them
together.
There may also be merit in considering an energy-adjusted
version of the MLI. Lipid typically yields approximately 38 kJ/g
(9 kcal/g) and carbohydrate yields approximately 17 kJ/g
(4 kcal/g). In an attempt to consider the amount of circulating
energy in the bloodstream at a given time, there may be utility
in adjusting the MLI equation to reﬂect the difference in energy
yield between carbohydrate and fat, which could be accom-
plished via an ‘adjusted metabolic load index’ (A-MLI):
A-MLI
kJ
dl
 
= TAG
mg
dl
 
´ 0001 g
mg
´ 38
kJ
g
 
+ Glu
mg
dl
 
´ 0001 g
mg
´ 17
kJ
g
 
:
For instance, if an individual was found to have TAG levels of
120mg/dl and glucose levels of 90mg/dl, their A-MLI would be
6·09 kJ/dl (1·44 kcal/dl). Thus, the A-MLI would provide an
equation through which to quantify or estimate the available
circulating energy from fat and carbohydrate. However, there
are some issues with the A-MLI, which include biasing towards
TAG and presenting somewhat unusual units (kJ/dl (kcal/dl)).
Nevertheless, the A-MLI may prove to be a valuable clinical tool
in assessing the metabolic state. Research comparing MLI and
A-MLI with regard to prediction of, and association with, health
outcomes would be valuable.
Utility of the metabolic load index
What are some ways or instances in which utilisation of the
MLI would be beneﬁcial or enhance our understanding of an
individual’s metabolic status? First and most clearly, use of the
MLI could better reveal the degree of metabolic challenge that
a person is experiencing either while fasting or after a meal.
This utility would be particularly applicable to patient popula-
tions, as it has already been previously discussed how ﬂuc-
tuations in postprandial glycaemia and lipaemia can be
cardiovascular risk factors. Speciﬁcally, it may be valuable to
develop a ‘cut point’ for fasting MLI, such as 200mg/dl,
as postprandial assessments may be too cumbersome in
certain clinical settings. Particular patient populations for which
assessing MLI would be valuable might include individuals with
diagnosed CVD or type 2 diabetes. As metabolism of lipids and
carbohydrates is so interrelated, consideration of the glycaemic
or lipaemic response together would be valuable.
MLI would also be useful in terms of standardising responses
across studies investigating postprandial metabolism. One of
the most difﬁcult aspects of compiling and comparing studies
either investigating postprandial lipaemia or glycaemia (when a
mixed meal is used) is the heterogeneity of test meal challenges
that are utilised in the investigations. Although differences in the
amount of total energy (and perhaps participants’ body mass)
would still need to be considered, MLI may help in comparing
across studies that use meals of different macronutrient
distribution but similar energetic value.
A current area of debate is the ideal proportion of macro-
nutrients that should be consumed in a healthy diet. If the MLI
response is similar between diets of different macronutrient
distribution but similar energetic load, it may make the focus on
select macronutrient proﬁles less prevalent.
Considerations of the metabolic load index
Given the novelty of the MLI, there are certainly considerations
to be made. First, it has been shown that dietary fructose leads
to postprandial metabolic responses that are different from
dietary glucose(87). Speciﬁcally, fructose consumption (com-
pared with glucose) as part of a mixed meal will lead to:
(1) a greater TAG response, particularly in the latter stages of a
postprandial assessment; (2) a comparatively negligible glucose
response; and (3) a much more tempered insulin response(87).
However, we assert that the different metabolic responses of
glucose and fructose do not represent a weakness of MLI,
but rather a strength. Considering the different metabolic
consequences of glucose and fructose, the outcomes of interest
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Fig. 3. Postprandial TAG responses to a high-fat meal with (▲) and without
(□) 75 g of added glucose. The TAG response is blunted in terms of both peak
value and time to peak when glucose is added to the high-fat meal. Incremental
AUC (iAUC) is 42% lower in the fat meal with added glucose compared with
the fat meal alone (P = 0·017). *Mean value was significantly different from that
of the meal with added glucose at the same time point (P< 0·05). Adapted with
permission from Westphal et al.(84). Diff, difference.
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are nevertheless the same: circulating glucose and TAG, the two
markers measured in the MLI. Thus, although fructose may lead
to a greater TAG response and a lower glucose response
compared with dietary glucose(87), this will be captured in the
MLI. If only considering the blood glucose response, one could
surmise that fructose is better to include in a mixed meal
because there is a much less blood glucose response. However,
utilising the MLI, it can be seen that fructose still has substantial
metabolic effects – though it more drastically alters the other
component of the MLI equation, TAG. Thus, we assert that a
strength of MLI is that it ‘throws a broader net’. In other words,
even though many nutrients clearly have differing metabolic
effects such as glucose and fructose, MLI is better equipped
than blood glucose or TAG assessment alone to capture the
metabolic challenge that the body is experiencing.
It would be valuable to determine an optimal postprandial
time point to assess MLI. For instance, it appears that TAG
measured 2 and 4 h after meal consumption have the strongest
association with cardiovascular events(50) and that TAG tend to
peak 4 h after a meal(88,89). In addition, one study has found that
measuring TAG 4 h post a high-fat meal is a suitable surrogate
for longer and more involved postprandial lipaemia assess-
ments(90). On the other hand, as previously discussed, post-
challenge glucose tolerance is typically assessed in the context
of a 2-h OGTT(11), and 2-h glucose values are strongly related to
CVD risk(12–14). Clearly, there are differences in the timing of
postprandial glucose and TAG responses and, consequently, in
the timing of assessment to best ascertain an individual’s disease
risk. Considering these differences, it is difﬁcult to state an
optimal, single time point at which to assess MLI in clinical and
research settings. It would be very worthwhile for future studies
to address this question using large data sets of postprandial
metabolic markers and disease risk outcomes.
Similarly, a logical question is as follows: which individuals
would beneﬁt most from ascertaining their fasting and post-
prandial MLI? An expert panel statement has suggested that
postprandial TAG assessments are most valuable in individuals
with fasting levels between 89 and 180mg/dl(91). The rationale
for this stance is that individuals with fasting TAG <89mg/dl
will typically show a negligible postprandial response, whereas
those with fasting TAG >180mg/dl will present an excessively
delayed and exaggerated postprandial lipaemic response such
that there is little diagnostic utility(91). In line with this, there
may be certain populations that could most beneﬁt diag-
nostically from determination of MLI. It could be that individuals
with very low or high fasting glucose and/or TAG levels may
not beneﬁt very much from the additional metabolic informa-
tion provided via MLI. However, we are hesitant to state which
individuals would and would not beneﬁt from fasting
and postprandial MLI assessment, given the current dearth of
evidence to support a conclusion. Further, as addressed
previously, with both glucose and TAG, postprandial values are
typically better predictors of CVD risk compared with fasting
values. Thus, there is no compelling evidence suggesting that
individuals with certain fasting MLI values would not beneﬁt
substantially from a postprandial MLI assessment. It would be
advantageous for future research to further explore this
concept.
Finally, it is likely that genetics inﬂuences the postprandial
MLI response. This supposition is based on the notion that
gene variation has been found to contribute to inter-individual
differences in both postprandial lipaemia and hyperglycaemia.
With regard to postprandial lipaemia, the most heavily studied
genetic regions have been the encoding of various apo genes,
such as APOA1(92) and APOC3(93), and genes encoding lipid
metabolism enzymes such as LPL(94) and HL (hepatic lipase)(95).
A few areas of genetic contribution to hyperglycaemia include
adiponectin gene polymorphisms(96,97), telomere length(98) and
transcription factor 7-like 2 (TCF7L2) variation(99), a transcrip-
tion factor that is to date the most substantial genetic contributor
to type 2 diabetes incidence(100). Clearly, as there are estab-
lished genetic contributors to both postprandial lipaemia and
hyperglycaemia, it is logical to assume that genetic factors
inﬂuence MLI as well.
Conclusion and future directions
It has been well established that postprandial glycaemia and
lipaemia are risk factors for CVD. Speciﬁcally, postprandial
glycaemia and lipaemia have been linked to increased disease
risk by way of oxidative stress, inﬂammation and endothelial
dysfunction, as well as other mechanisms. Although carbohy-
drate and lipids ultimately share similar clearing mechanisms,
the ﬂuctuations in these substrates in daily life, or experimen-
tally following a test meal challenge, have historically only been
considered separately. However, in light of evidence that
postprandial glycaemia and lipaemia are not independent
of one another, it does not seem unreasonable to consider both
of these phenomena together in a single index. The concept of
MLI, which is the sum of blood glucose and TAG, is valuable in
that it considers the total metabolic challenge that the body is
experiencing, either at a single time point or over time. In our
opinion, the MLI carries signiﬁcant potential clinical utility. It
would be worthwhile for future investigations to assess MLI in
the context of disease risk, investigating the relationship
between MLI and markers of inﬂammation, oxidative stress,
endothelial dysfunction and other risk markers. However,
currently we do not know whether adding the two outcomes in
a 1:1 ratio is the most accurate way to predict risk when con-
sidering glucose and TAG together. Thus, future work should
seek to derive the best equation for assessing glycaemia and
lipaemia simultaneously by using data from clinical populations
and longitudinal studies.
Acknowledgements
The authors contributed to the completion of the present review
in the following ways: S. R. E. helped develop the manuscript
idea and wrote the manuscript, M. D. H. helped develop the
manuscript idea and edited the manuscript, C. S. T. edited
the manuscript and provided vital feedback, S. P. K. edited the
manuscript and provided vital feedback and S. K. R. helped
develop the manuscript idea and edited the manuscript.
This research received no speciﬁc grant from any funding
agency, commercial or not-for-proﬁt sectors.
The authors declare they have no conﬂicts of interest.
1560 S. R. Emerson et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114516003585
Downloaded from https://www.cambridge.org/core. Kansas State University Libraries, on 08 Aug 2017 at 16:15:58, subject to the Cambridge Core terms of use, available at
References
1. Ceriello A (2005) Postprandial hyperglycemia and diabetes
complications: is it time to treat? Diabetes 54, 1–7.
2. O’Keefe JH & Bell DS (2007) Postprandial hyperglycemia/
hyperlipidemia (postprandial dysmetabolism) is a cardio-
vascular risk factor. Am J Cardiol 100, 899–904.
3. Sies H, Stahl W & Sevanian A (2005) Nutritional, dietary and
postprandial oxidative stress. J Nutr 135, 969–972.
4. Alberti KG & Zimmet PZ (1998) Deﬁnition, diagnosis and
classiﬁcation of diabetes mellitus and its complications. Part 1:
diagnosis and classiﬁcation of diabetes mellitus. Provisional
report of a WHO consultation. Diabet Med 15, 539–553.
5. Stratton IM, Adler AI, Neil HA, et al. (2000) Association of
glycaemia with macrovascular and microvascular complica-
tions of type 2 diabetes (UKPDS 35): prospective
observational study. BMJ 321, 405–412.
6. Emerging Risk Factors Collaboration (2010) Diabetes melli-
tus, fasting blood glucose concentration, and risk of vascular
disease: a collaborative meta-analysis of 102 prospective
studies. Lancet 375, 2215–2222.
7. Williams DE, Cadwell BL, Cheng YJ, et al. (2005) Prevalence
of impaired fasting glucose and its relationship with cardio-
vascular disease risk factors in US adolescents, 1999–2000.
Pediatrics 116, 1122–1126.
8. Monnier L, Lapinski H & Colette C (2003) Contributions of
fasting and postprandial plasma glucose increments to the
overall diurnal hyperglycemia of type 2 diabetic patients:
variations with increasing levels of HbA(1c). Diabetes Care
26, 881–885.
9. Tominaga M, Eguchi H, Manaka H, et al. (1999) Impaired
glucose tolerance is a risk factor for cardiovascular disease,
but not impaired fasting glucose. The Funagata
Diabetes Study. Diabetes Care 22, 920–924.
10. Blake DR, Meigs JB, Muller DC, et al. (2004) Impaired glu-
cose tolerance, but not impaired fasting glucose, is asso-
ciated with increased levels of coronary heart disease risk
factors: results from the Baltimore Longitudinal Study
on Aging. Diabetes 53, 2095–2100.
11. Matsuda M & DeFronzo RA (1999) Insulin sensitivity indices
obtained from oral glucose tolerance testing: comparison
with the euglycemic insulin clamp. Diabetes Care 22,
1462–1470.
12. Levitan EB, Song Y, Ford ES, et al. (2004) Is nondiabetic
hyperglycemia a risk factor for cardiovascular disease?:
a meta-analysis of prospective studies. Arch Intern Med 164,
2147–2155.
13. Lowe LP, Liu K, Greenland P, et al. (1997) Diabetes,
asymptomatic hyperglycemia, and 22-year mortality in black
and white men. The Chicago Heart Association Detection
Project in Industry Study. Diabetes Care 20, 163–169.
14. Pekkanen J, Tuomilehto J, Qiao Q, et al. (1999) Glucose tol-
erance and mortality: comparison of WHO and American
Diabetes Association diagnostic criteria. Lancet 354, 617–621.
15. Balkau B, Shipley M, Jarrett RJ, et al. (1998) High blood
glucose concentration is a risk factor for mortality in middle-
aged nondiabetic men. 20-year follow-up in the Whitehall
Study, the Paris Prospective Study, and the Helsinki
Policemen Study. Diabetes Care 21, 360–367.
16. Ducimetiere P, Eschwege E, Papoz L, et al. (1980)
Relationship of plasma insulin levels to the incidence of
myocardial infarction and coronary heart disease mortality in
a middle-aged population. Diabetologia 19, 205–210.
17. Pyörälä K, Savolainen E, Lehtovirta E, et al. (1979) Glucose
tolerance and coronary heart disease: Helsinki
Policemen Study. J Chronic Dis 32, 729–745.
18. Reid D, Hamilton P, Keen H, et al. (1974) Cardiorespiratory
disease and diabetes among middle-aged male civil servants:
a study of screening and intervention. Lancet 303, 469–473.
19. Hanefeld M, Fischer S, Julius U, et al. (1996) Risk factors for
myocardial infarction and death in newly detected NIDDM:
the Diabetes Intervention Study, 11-year follow-up. Diabeto-
logia 39, 1577–1583.
20. Wolever TM, Chiasson JL, Csima A, et al. (1998) Variation of
postprandial plasma glucose, palatability, and symptoms
associated with a standardized mixed test meal versus 75 g
oral glucose. Diabetes Care 21, 336–340.
21. Chiasson J, Josse RG, Gomis R, et al. (2002) Acarbose for
prevention of type 2 diabetes mellitus: the STOP-NIDDM
randomised trial. Lancet 359, 2072–2077.
22. Chiasson J, Josse RG, Gomis R, et al. (2003) Acarbose
treatment and the risk of cardiovascular disease and hyper-
tension in patients with impaired glucose tolerance: the
STOP-NIDDM trial. JAMA 290, 486–494.
23. Hanefeld M, Cagatay M, Petrowitsch T, et al. (2004) Acar-
bose reduces the risk for myocardial infarction in type 2
diabetic patients: meta-analysis of seven long-term studies.
Eur Heart J 25, 10–16.
24. Esposito K, Giugliano D, Nappo F, et al. (2004) Regression
of carotid atherosclerosis by control of postprandial hyper-
glycemia in type 2 diabetes mellitus. Circulation 110,
214–219.
25. Reaven GM (1988) Banting lecture 1988. Role of insulin
resistance in human disease. Diabetes 37, 1595–1607.
26. Swislocki A, Chen Y, Golay A, et al. (1987) Insulin sup-
pression of plasma-free fatty acid concentration in normal
individuals and patients with type 2 (non-insulin-dependent)
diabetes. Diabetologia 30, 622–626.
27. Ferrannini E, Barrett EJ, Bevilacqua S, et al. (1983) Effect of
fatty acids on glucose production and utilization in man.
J Clin Invest 72, 1737–1747.
28. Jorgensen RG, Russo L, Mattioli L, et al. (1988) Early detec-
tion of vascular dysfunction in type I diabetes. Diabetes 37,
292–296.
29. Marfella R, Verrazzo G, Acampora R, et al. (1995) Glu-
tathione reverses systemic hemodynamic changes induced
by acute hyperglycemia in healthy subjects. Am J Physiol
268, Suppl. 6, E1167–E1173.
30. Kawano H, Motoyama T, Hirashima O, et al. (1999) Hyper-
glycemia rapidly suppresses ﬂow-mediated endothelium-
dependent vasodilation of brachial artery. J Am Coll Cardiol
34, 146–154.
31. Shige H, Ishikawa T, Suzukawa M, et al. (1999)
Endothelium-dependent ﬂow-mediated vasodilation in the
postprandial state in type 2 diabetes mellitus. Am J Cardiol
84, 1272–1274.
32. Brownlee M (2001) Biochemistry and molecular cell biology
of diabetic complications. Nature 414, 813–820.
33. Sakamoto T, Ogawa H, Kawano H, et al. (2000) Rapid
change of platelet aggregability in acute hyperglycemia
detection by a novel laser-light scattering method. Thromb
Haemost 83, 475–479.
34. Ceriello A, Giacomello R, Stel G, et al. (1995)
Hyperglycemia-induced thrombin formation in diabetes.
The possible role of oxidative stress. Diabetes 44, 924–928.
35. Jones RL & Peterson CM (1979) Reduced ﬁbrinogen survival
in diabetes mellitus. A reversible phenomenon. J Clin Invest
63, 485–493.
36. Nappo F, Esposito K, Ciofﬁ M, et al. (2002) Postprandial
endothelial activation in healthy subjects and in type 2
diabetic patients: role of fat and carbohydrate meals. J Am
Coll Cardiol 39, 1145–1150.
Glycaemia, lipaemia and metabolic load index 1561
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114516003585
Downloaded from https://www.cambridge.org/core. Kansas State University Libraries, on 08 Aug 2017 at 16:15:58, subject to the Cambridge Core terms of use, available at
37. Esposito K, Nappo F, Marfella R, et al. (2002) Inﬂammatory
cytokine concentrations are acutely increased by hypergly-
cemia in humans: role of oxidative stress. Circulation 106,
2067–2072.
38. Ceriello A, Falleti E, Motz E, et al. (1998) Hyperglycemia-
induced circulating ICAM-1 increase in diabetes mellitus: the
possible role of oxidative stress. Horm Metab Res 30, 146–149.
39. Diwadkar VA, Anderson JW, Bridges SR, et al. (1999) Post-
prandial low-density lipoproteins in type 2 diabetes are
oxidized more extensively than fasting diabetes and control
samples. Proc Soc Exp Biol Med 222, 178–184.
40. Ceriello A, Bortolotti N, Motz E, et al. (1999) Meal-induced
oxidative stress and low-density lipoprotein oxidation in
diabetes: the possible role of hyperglycemia. Metab Clin Exp
48, 1503–1508.
41. Wilson PW, D’Agostino RB, Levy D, et al. (1998) Prediction
of coronary heart disease using risk factor categories.
Circulation 97, 1837–1847.
42. Gotto AM (1998) Triglyceride as a risk factor for coronary
artery disease. Am J Cardiol 82, 22–25.
43. Wood PD, Stefanick ML, Williams PT, et al. (1991) The
effects on plasma lipoproteins of a prudent weight-reducing
diet, with or without exercise, in overweight men
and women. N Engl J Med 325, 461–466.
44. Jeppesen J, Hein HO, Suadicani P, et al. (1998) Triglyceride
concentration and ischemic heart disease: an eight-year
follow-up in the Copenhagen Male Study. Circulation 97,
1029–1036.
45. Hokanson JE & Austin MA (1996) Plasma triglyceride level is
a risk factor for cardiovascular disease independent of high-
density lipoprotein cholesterol level: a meta-analysis of
population-based prospective studies. J Cardiovasc Risk 3,
213–219.
46. Patsch JR, Miesenbock G, Hopferwieser T, et al. (1992)
Relation of triglyceride metabolism and coronary artery
disease. Studies in the postprandial state. Arterioscler
Thromb 12, 1336–1345.
47. Peddie MC, Rehrer NJ & Perry TL (2012) Physical activity
and postprandial lipidemia: are energy expenditure and
lipoprotein lipase activity the real modulators of the positive
effect? Prog Lipid Res 51, 11–22.
48. Patsch JR, Karlin JB, Scott LW, et al. (1983) Inverse rela-
tionship between blood levels of high density lipoprotein
subfraction 2 and magnitude of postprandial lipemia.
Proc Natl Acad Sci U S A 80, 1449–1453.
49. Karpe F, Steiner G, Uffelman K, et al. (1994) Postprandial
lipoproteins and progression of coronary atherosclerosis.
Atherosclerosis 106, 83–97.
50. Bansal S, Buring JE, Rifai N, et al. (2007) Fasting compared
with nonfasting triglycerides and risk of cardiovascular
events in women. JAMA 298, 309–316.
51. Tabas I, Williams KJ & Boren J (2007) Subendothelial lipo-
protein retention as the initiating process in atherosclerosis:
update and therapeutic implications. Circulation 116,
1832–1844.
52. Borén J, Matikainen N, Adiels M, et al. (2014) Postprandial
hypertriglyceridemia as a coronary risk factor. Clin Chim
Acta 431, 131–142.
53. Boquist S, Ruotolo G, Tang R, et al. (1999) Alimentary
lipemia, postprandial triglyceride-rich lipoproteins, and
common carotid intima-media thickness in healthy, middle-
aged men. Circulation 100, 723–728.
54. Teno S, Uto Y, Nagashima H, et al. (2000) Association of
postprandial hypertriglyceridemia and carotid intima-media
thickness in patients with type 2 diabetes. Diabetes Care 23,
1401–1406.
55. van Oostrom AJ, Sijmonsma TP, Verseyden C, et al. (2003)
Postprandial recruitment of neutrophils may contribute to
endothelial dysfunction. J Lipid Res 44, 576–583.
56. Van Wijk J, Cabezas MC, Coll B, et al. (2006) Effects of
rosiglitazone on postprandial leukocytes and cytokines in
type 2 diabetes. Atherosclerosis 186, 152–159.
57. Vogel RA, Corretti MC & Plotnick GD (1997) Effect of a
single high-fat meal on endothelial function in healthy
subjects. Am J Cardiol 79, 350–354.
58. Erridge C, Attina T, Spickett CM, et al. (2007) A high-fat meal
induces low-grade endotoxemia: evidence of a novel
mechanism of postprandial inﬂammation. Am J Clin Nutr
86, 1286–1292.
59. Wildman RE & Medeiros DM (1999) Advanced Human
Nutrition. Boca Raton, FL: CRC Press.
60. Czech MP & Corvera S (1999) Signaling mechanisms that
regulate glucose transport. J Biol Chem 274, 1865–1868.
61. Mashek DG & Coleman RA (2006) Cellular fatty acid uptake:
the contribution of metabolism. Curr Opin Lipidol 17, 274–278.
62. Haag M & Dippenaar NG (2005) Dietary fats, fatty acids and
insulin resistance: short review of a multifaceted connection.
Med Sci Monit 11, RA359–RA367.
63. Hulbert AJ, Turner N, Storlien L, et al. (2005) Dietary fats and
membrane function: implications for metabolism and dis-
ease. Biol Rev Camb Philos Soc 80, 155–169.
64. Randle P, Garland P, Hales C, et al. (1963) The glucose fatty-
acid cycle its role in insulin sensitivity and the metabolic
disturbances of diabetes mellitus. Lancet 281, 785–789.
65. Storlien LH, Jenkins AB, Chisholm DJ, et al. (1991) Inﬂuence
of dietary fat composition on development of insulin resis-
tance in rats: relationship to muscle triglyceride and ω-3 fatty
acids in muscle phospholipid. Diabetes 40, 280–289.
66. Lovejoy JC (1999) Dietary fatty acids and insulin resistance.
Curr Atheroscler Rep 1, 215–220.
67. Fernie AR, Carrari F & Sweetlove LJ (2004) Respiratory
metabolism: glycolysis, the TCA cycle and mitochondrial
electron transport. Curr Opin Plant Biol 7, 254–261.
68. Lunt SY & Vander Heiden MG (2011) Aerobic glycolysis:
meeting the metabolic requirements of cell proliferation.
Annu Rev Cell Dev Biol 27, 441–464.
69. Ceriello A & Motz E (2004) Is oxidative stress the pathogenic
mechanism underlying insulin resistance, diabetes, and
cardiovascular disease? The common soil hypothesis
revisited. Arterioscler Thromb Vasc Biol 24, 816–823.
70. Vincent AM, McLean LL, Backus C, et al. (2005) Short-term
hyperglycemia produces oxidative damage and apoptosis in
neurons. FASEB J 19, 638–640.
71. Jay D, Hitomi H & Griendling KK (2006) Oxidative stress and
diabetic cardiovascular complications. Free Radic Biol Med
40, 183–192.
72. Rocha VZ & Libby P (2009) Obesity, inﬂammation, and
atherosclerosis. Nat Rev Cardiol 6, 399–409.
73. Hansson GK (2005) Inﬂammation, atherosclerosis, and
coronary artery disease. N Engl J Med 352, 1685–1695.
74. Kita T, Kume N, Ishii K, et al. (1999) Oxidized LDL and
expression of monocyte adhesion molecules. Diabetes Res
Clin Pract 45, 123–126.
75. Hajjar DP & Haberland ME (1997) Lipoprotein trafﬁcking in
vascular cells. Molecular Trojan horses and cellular sabo-
teurs. J Biol Chem 272, 22975–22978.
76. Maziere C, Auclair M, Djavaheri‐Mergny M, et al. (1996)
Oxidized low density lipoprotein induces activation of the
transcription factor NFκB in ﬁbroblasts, endothelial and
smooth muscle cells. IUBMB Life 39, 1201–1207.
77. Weissman A, Lowenstein L, Peleg A, et al. (2006) Power
spectral analysis of heart rate variability during the 100-g oral
1562 S. R. Emerson et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114516003585
Downloaded from https://www.cambridge.org/core. Kansas State University Libraries, on 08 Aug 2017 at 16:15:58, subject to the Cambridge Core terms of use, available at
glucose tolerance test in pregnant women. Diabetes Care
29, 571–574.
78. Ferreira AC, Peter AA, Mendez AJ, et al. (2004) Postprandial
hypertriglyceridemia increases circulating levels of endo-
thelial cell microparticles. Circulation 110, 3599–3603.
79. Emerson SR, Kurti SP, Snyder BS, et al. (2016) Effects of
thirty and sixty minutes of moderate-intensity aerobic
exercise on postprandial lipemia and inﬂammation in
overweight men: a randomized cross-over study. J Int Soc
Sports Nutr 13, 1.
80. Albrink MJ, Fitzgerald JR & Man EB (1958) Reduction of
alimentary lipemia by glucose. Metabolism 7, 162–171.
81. Mann J, Truswell A & Pimstone B (1971) The different effects
of oral sucrose and glucose on alimentary lipaemia. Clin Sci
41, 123–129.
82. Cohen JC & Schall R (1988) Reassessing the effects of simple
carbohydrates on the serum triglyceride responses to
fat meals. Am J Clin Nutr 48, 1031–1034.
83. Knuth ND, Remias DB & Horowitz JF (2008) Adding
carbohydrate to a high-fat meal blunts postprandial lipemia
in women and reduces meal-derived fatty acids in systemic
circulation. Appl Physiol Nutr Metab 33, 315–325.
84. Westphal S, Leodolter A, Kahl S, et al. (2002) Addition of
glucose to a fatty meal delays chylomicrons and suppresses
VLDL in healthy subjects. Eur J Clin Invest 32, 322–327.
85. Collier G & O’Dea K (1983) The effect of coingestion of fat
on the glucose, insulin, and gastric inhibitory polypeptide
responses to carbohydrate and protein. Am J Clin Nutr 37,
941–944.
86. Ercan N, Gannon MC & Nuttall FQ (1994) Effect of added fat
on the plasma glucose and insulin response to ingested
potato given in various combinations as two meals in normal
individuals. Diabetes Care 17, 1453–1459.
87. Chong MF, Fielding BA & Frayn KN (2007) Mechanisms
for the acute effect of fructose on postprandial lipemia. Am J
Clin Nutr 85, 1511–1520.
88. Langsted A, Freiberg JJ & Nordestgaard BG (2008) Fasting
and nonfasting lipid levels: inﬂuence of normal food intake
on lipids, lipoproteins, apolipoproteins, and cardiovascular
risk prediction. Circulation 118, 2047–2056.
89. Mihas C, Kolovou GD, Mikhailidis DP, et al. (2011) Diag-
nostic value of postprandial triglyceride testing in healthy
subjects: a meta-analysis. Curr Vasc Pharmacol 9, 271–280.
90. Weiss EP, Fields DA, Mittendorfer B, et al. (2008) Reprodu-
cibility of postprandial lipemia tests and validity of an
abbreviated 4-hour test. Metab Clin Exp 57, 1479–1485.
91. Kolovou GD, Mikhailidis DP, Kovar J, et al. (2011) Assess-
ment and clinical relevance of non-fasting and postprandial
triglycerides: an expert panel statement. Curr Vasc Phar-
macol 9, 258–270.
92. Delgado-Lista J, Perez-Jimenez F, Ruano J, et al. (2010)
Effects of variations in the APOA1/C3/A4/A5 gene cluster on
different parameters of postprandial lipid metabolism in
healthy young men. J Lipid Res 51, 63–73.
93. Perez-Martinez P, Lopez-Miranda J, Perez-Jimenez F, et al.
(2008) Inﬂuence of genetic factors in the modulation of
postprandial lipemia. Atheroscler Suppl 9, 49–55.
94. López-Miranda J, Cruz G, Gómez P, et al. (2004) The inﬂu-
ence of lipoprotein lipase gene variation on postprandial
lipoprotein metabolism. J Clin Endocrinol Metab 89,
4721–4728.
95. Jiménez-Gómez Y, Pérez-Jiménez F, Marín C, et al. (2008)
The − 250G/A polymorphism in the hepatic lipase gene
promoter inﬂuences the postprandial lipemic response in
healthy men. Nutr Metab Cardiovasc Dis 18, 173–181.
96. Fumeron F, Aubert R, Siddiq A, et al. (2004) Adiponectin gene
polymorphisms and adiponectin levels are independently
associated with the development of hyperglycemia during a
3-year period: the epidemiologic data on the insulin resistance
syndrome prospective study. Diabetes 53, 1150–1157.
97. Hara K, Boutin P, Mori Y, et al. (2002) Genetic variation in
the gene encoding adiponectin is associated with an
increased risk of type 2 diabetes in the Japanese population.
Diabetes 51, 536–540.
98. Salpea KD, Talmud PJ, Cooper JA, et al. (2010) Association
of telomere length with type 2 diabetes, oxidative stress and
UCP2 gene variation. Atherosclerosis 209, 42–50.
99. Cauchi S, Meyre D, Choquet H, et al. (2006) TCF7L2 varia-
tion predicts hyperglycemia incidence in a French general
population: the data from an epidemiological study on the
Insulin Resistance Syndrome (DESIR) study. Diabetes 55,
3189–3192.
100. Vaquero AR, Ferreira NE, Omae SV, et al. (2012) Using gene-
network landscape to dissect genotype effects of TCF7L2
genetic variant on diabetes and cardiovascular risk. Physiol
Genomics 44, 903–914.
Glycaemia, lipaemia and metabolic load index 1563
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114516003585
Downloaded from https://www.cambridge.org/core. Kansas State University Libraries, on 08 Aug 2017 at 16:15:58, subject to the Cambridge Core terms of use, available at
